The board of directors of Sanofi India has approved an exclusive distribution and promotion agreement between SIL and Emcure Pharmaceuticals for SIL’s Cardiovascular products in India.
Emcure Pharmaceuticals will exclusively distribute and promote the company’s cardiovascular range of products that include brands such as Cardace, Clexane, Targocid, Lasix and Lasilactone.
While SIL will continue to own, import, and manufacture these brands across Sanofi’s plants in India and internationally, Emcure will leverage its strengths to engage healthcare professionals and expand reach of these therapeutic solutions for patients who need them across all areas of India.
Sanofi India’s concerned employees will have the opportunity to work at Emcure.
Rodolfo Hrosz, managing director, Sanofi India, says, “Sanofi has been committed to improving the lives of patients in India through its range of products. Sanofi India has many cardiovascular products which are leaders in their respective categories. With Emcure’s wide presence across India, our partnership will benefit both HCPs (Healthcare Professionals) and patients by creating the opportunity to maximize the reach of our CV products.”
Satish Mehta, chief executive officer and managing director, Emcure Pharmaceuticals, says, “At Emcure Pharmaceuticals our competitive advantage lies in our established presence in all major therapeutic areas including cardiology. We’re delighted to have the opportunity to partner with Sanofi India as their range of well-established cardiovascular brands will complement our strong CV portfolio, making it a highly robust offering. Towards this endeavor, Sanofi’s relevant team also has the opportunity to join us.”
